Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.40
PCRX's Cash to Debt is ranked lower than
52% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. PCRX: 1.40 )
Ranked among companies with meaningful Cash to Debt only.
PCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.62 Max: No Debt
Current: 1.4
Equity to Asset 0.57
PCRX's Equity to Asset is ranked lower than
59% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PCRX: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
PCRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.38 Max: 0.66
Current: 0.57
-0.82
0.66
Interest Coverage 2.30
PCRX's Interest Coverage is ranked lower than
90% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. PCRX: 2.30 )
Ranked among companies with meaningful Interest Coverage only.
PCRX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 2.3
F-Score: 7
Z-Score: 8.14
M-Score: -2.52
WACC vs ROIC
18.56%
11.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 7.53
PCRX's Operating margin (%) is ranked lower than
53% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. PCRX: 7.53 )
Ranked among companies with meaningful Operating margin (%) only.
PCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -325.77  Med: -155.95 Max: -2.61
Current: 7.53
-325.77
-2.61
Net-margin (%) 4.21
PCRX's Net-margin (%) is ranked lower than
58% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. PCRX: 4.21 )
Ranked among companies with meaningful Net-margin (%) only.
PCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -300.62  Med: -186.44 Max: -6.94
Current: 4.21
-300.62
-6.94
ROE (%) 5.55
PCRX's ROE (%) is ranked lower than
54% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. PCRX: 5.55 )
Ranked among companies with meaningful ROE (%) only.
PCRX' s ROE (%) Range Over the Past 10 Years
Min: -119.34  Med: -91.62 Max: -12.92
Current: 5.55
-119.34
-12.92
ROA (%) 3.00
PCRX's ROA (%) is ranked lower than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. PCRX: 3.00 )
Ranked among companies with meaningful ROA (%) only.
PCRX' s ROA (%) Range Over the Past 10 Years
Min: -67.11  Med: -47.25 Max: -5.53
Current: 3
-67.11
-5.53
ROC (Joel Greenblatt) (%) 18.63
PCRX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. PCRX: 18.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -291.9  Med: -126.22 Max: -7.39
Current: 18.63
-291.9
-7.39
Revenue Growth (3Y)(%) 80.60
PCRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PCRX: 80.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PCRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67  Med: -58.30 Max: 80.6
Current: 80.6
-67
80.6
EPS Growth (3Y)(%) -47.20
PCRX's EPS Growth (3Y)(%) is ranked lower than
94% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. PCRX: -47.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: -66.70 Max: -47.2
Current: -47.2
-68.5
-47.2
» PCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PCRX Guru Trades in Q1 2015

Joel Greenblatt 9,319 sh (New)
Ron Baron 82,380 sh (+22.79%)
RS Investment Management 610,987 sh (+2.80%)
Ken Fisher 4,800 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Mariko Gordon 659,998 sh (-4.30%)
» More
Q2 2015

PCRX Guru Trades in Q2 2015

George Soros 531,800 sh (New)
Mariko Gordon 667,877 sh (+1.19%)
Ken Fisher 4,800 sh (unchged)
Ron Baron Sold Out
Joel Greenblatt Sold Out
RS Investment Management Sold Out
» More
Q3 2015

PCRX Guru Trades in Q3 2015

Jim Simons 108,500 sh (New)
Ron Baron 6,900 sh (New)
Paul Tudor Jones 8,090 sh (New)
Mariko Gordon 1,042,012 sh (+56.02%)
Ken Fisher 5,950 sh (+23.96%)
George Soros Sold Out
» More
Q4 2015

PCRX Guru Trades in Q4 2015

Ken Fisher 6,197 sh (+4.15%)
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on Pacira Pharmaceuticals - Mar 05, 2014

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a vertically integrated (IP to manufacturing) pharmaceutical company. Its main line of business is the sale of a drug called EXPAREL, which was approved by the FDA in October 2011 and launched in the U.S. in April 2012. EXPAREL is a pain control drug (using slow release bupivacaine) injected directly into the wound/cut site during a surgical procedure, prior to closing the incision. It is also being studied for use as a nerve block agent for additional procedures. Bupivacaine is a well-known drug that has been used for decades during surgery. Its safety profile is well understood. The key advantage of EXPAREL over generic bupivacaine is that it incorporates a proprietary time-release "wrapper" called DepoFoam that lets the pain relief delivered by bupivacaine last for up to three days post-surgery. This enables reduced usage of dangerous opiates and other treatments, such as pain balls. In the end, we believe that based on clinical studies, EXPAREL is cheaper, safer and more effective than current pain management practices. We believe that EXPAREL has significant IP protection and has limited potential competitors.

Uptake among large hospital formularies has been brisk, and EXPAREL has been at least initially purchased at over 75% of the top 100 hospitals in the U.S. and most of the top 500 hospitals.Yet penetration of the potential $40 million procedure market is still minimal. Most current sales are for soft tissue procedures, but orthopedic studies also look promising. EXPAREL did about $14.5 million in sales in 2012, which grew to about $76 million in 2013 based on information recently released by the company. The fourth quarter annualized run rate of the drug is over $120 million.This means that the company is going to have to expand capacity from its current $100 million volume plant. It has built capacity for up to $400 million in sales, and is awaiting what we believe will be near term approval from the FDA on the plant. We believe EXPAREL represents a worldwide market opportunity of potentially billions of dollars and that it is just at the start of its overall volume penetration.Additionally, the company has longer term plans to use its DepoFoam "wrapper" technology on other drugs, including methotrexate (for rheumatoid arthritis). If this massive opportunity set is properly exploited, we believe that Pacira could become a billion dollar revenue company within a few years, and earnings per share could ultimately exceed $10 on EXPAREL alone. At a current price of $65, shares trade at only 6.5x this level, and it's possible that they could trade at 15-20x if growth hits our expectations.

From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 213.67
PCRX's P/E(ttm) is ranked lower than
97% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. PCRX: 213.67 )
Ranked among companies with meaningful P/E(ttm) only.
PCRX' s P/E(ttm) Range Over the Past 10 Years
Min: 146.01  Med: 247.33 Max: 726.49
Current: 213.67
146.01
726.49
Forward P/E 16.92
PCRX's Forward P/E is ranked lower than
52% of the 403 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.75 vs. PCRX: 16.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 214.50
PCRX's PE(NRI) is ranked lower than
97% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. PCRX: 214.50 )
Ranked among companies with meaningful PE(NRI) only.
PCRX' s PE(NRI) Range Over the Past 10 Years
Min: 146.56  Med: 248.24 Max: 733.09
Current: 214.5
146.56
733.09
P/B 10.20
PCRX's P/B is ranked lower than
99.99% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. PCRX: 10.20 )
Ranked among companies with meaningful P/B only.
PCRX' s P/B Range Over the Past 10 Years
Min: 3.47  Med: 12.52 Max: 73.22
Current: 10.2
3.47
73.22
P/S 9.61
PCRX's P/S is ranked lower than
95% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. PCRX: 9.61 )
Ranked among companies with meaningful P/S only.
PCRX' s P/S Range Over the Past 10 Years
Min: 0.39  Med: 14.41 Max: 30.44
Current: 9.61
0.39
30.44
POCF 86.44
PCRX's POCF is ranked lower than
86% of the 631 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.19 vs. PCRX: 86.44 )
Ranked among companies with meaningful POCF only.
PCRX' s POCF Range Over the Past 10 Years
Min: 59.06  Med: 100.08 Max: 818.77
Current: 86.44
59.06
818.77
EV-to-EBIT 112.20
PCRX's EV-to-EBIT is ranked lower than
95% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.51 vs. PCRX: 112.20 )
Ranked among companies with meaningful EV-to-EBIT only.
PCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -794  Med: -10.05 Max: 543.4
Current: 112.2
-794
543.4
EV-to-EBITDA 70.39
PCRX's EV-to-EBITDA is ranked lower than
92% of the 847 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.31 vs. PCRX: 70.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
PCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -264.3  Med: -9.70 Max: 876.1
Current: 70.39
-264.3
876.1
Current Ratio 1.60
PCRX's Current Ratio is ranked lower than
66% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. PCRX: 1.60 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.61 Max: 10.16
Current: 1.6
0.81
10.16
Quick Ratio 1.22
PCRX's Quick Ratio is ranked lower than
64% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. PCRX: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.46 Max: 9.31
Current: 1.22
0.68
9.31
Days Inventory 198.50
PCRX's Days Inventory is ranked lower than
80% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. PCRX: 198.50 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 65.70 Max: 105.63
Current: 198.5
31.07
105.63
Days Sales Outstanding 39.18
PCRX's Days Sales Outstanding is ranked higher than
82% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. PCRX: 39.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 41.30 Max: 67.76
Current: 39.18
29.85
67.76
Days Payable 43.32
PCRX's Days Payable is ranked lower than
75% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. PCRX: 43.32 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 75.01 Max: 246.51
Current: 43.32
20.45
246.51

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 29.11
PCRX's Price/Net Current Asset Value is ranked lower than
87% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.29 vs. PCRX: 29.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PCRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 10.03  Med: 47.01 Max: 414.29
Current: 29.11
10.03
414.29
Price/Tangible Book 11.82
PCRX's Price/Tangible Book is ranked lower than
84% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. PCRX: 11.82 )
Ranked among companies with meaningful Price/Tangible Book only.
PCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.09  Med: 16.21 Max: 99.99
Current: 11.82
5.09
99.99
Price/Median PS Value 0.66
PCRX's Price/Median PS Value is ranked higher than
85% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. PCRX: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
PCRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 1.03 Max: 1.76
Current: 0.66
0.03
1.76
Price/Graham Number 10.61
PCRX's Price/Graham Number is ranked lower than
96% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. PCRX: 10.61 )
Ranked among companies with meaningful Price/Graham Number only.
PCRX' s Price/Graham Number Range Over the Past 10 Years
Min: 7.53  Med: 14.26 Max: 20.99
Current: 10.61
7.53
20.99
Earnings Yield (Greenblatt) (%) 0.85
PCRX's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PCRX: 0.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.50 Max: 1.2
Current: 0.85
0.2
1.2

More Statistics

Revenue(Mil) $241
EPS $ 0.27
Beta2.29
Short Percentage of Float26.85%
52-Week Range $35.78 - 121.95
Shares Outstanding(Mil)36.76

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 248 331 468 629
EPS($) 1.12 1.95 3.41 5.08
EPS without NRI($) 1.12 1.95 3.41 5.08

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:82P.Germany,
Pacira Pharmaceuticals Inc was incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed its name to Pacira, Inc. in June 2007. The Company is a pharmaceutical company engaged in the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. As of December 31, 2013, its commercial stage products are EXPAREL and DepoCyt. EXPAREL is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia and was approved by the FDA on October 28, 2011. The Company commercially launched EXPAREL in April 2012. It ship EXPAREL directly to the end user based on orders placed to wholesalers or directly to the Company and have no product held by wholesalers. DepoCyt is a sustained release liposomal formulation of the chemotherapeutic agent cytarabine and is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt was granted accelerated approval by the FDA in 1999 and full approval in 2007. The Company sells DepoCyt to its commercial partners located in the U.S. and Europe. The Company's trademarks include Pacira, EXPAREL, DepoCyt and DepoCyte. The Company's customers are AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company. Its competitors include organizations such as multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. In addition to regulations in the United States, it is subject to various foreign regulations governing clinical trials and the commercial sales and distribution of its products.
» More Articles for PCRX

Headlines

Articles On GuruFocus.com
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Mariko Gordon's First Quarter Top Five May 15 2014 
Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

More From Other Websites
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) to Ring The Nasdaq Stock Market Opening Bell Feb 02 2016
Pacira Pharma upgraded by BofA/Merrill Jan 29 2016
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 22,... Jan 22 2016
Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : January 12, 2016 Jan 12 2016
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 12,... Jan 12 2016
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 08 2016
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 07 2016
Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million Jan 07 2016
Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million Jan 07 2016
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 28 2015
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 28 2015
Pacira Rose on the FDA’s Favorable Decision on EXPAREL Dec 21 2015
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Dec 18 2015
Pacira Resolves Litigation Related to Exparel with the FDA Dec 15 2015
What's next for Valeant? Dec 15 2015
Pacira Pharma Soars on Settled FDA Case Dec 15 2015
Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute Dec 15 2015
Skyepharma skips on Pacira's Exparel agreement with FDA Dec 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK